Literature DB >> 34151208

14,17,18-Trihydroxy-Eicosatetraenoic Acid: A Novel Pro-Resolving Lipid Mediator from Marine Microalgae.

Hans Jagusch1, Markus Werner2, Duco Koenis3, Jesmond Dalli3, Oliver Werz2, Georg Pohnert1.   

Abstract

Specialized pro-resolving mediators (SPMs) are enzymatically oxygenated derivatives of polyunsaturated fatty acids that function as central immunoregulators in mammals. Among them are resolvins (Rvs) that stimulate the clearance of harmful stimuli and limit pro-inflammatory processes. Because of their beneficial features and their high potency, SPMs are promising molecules for anti-inflammatory therapy. Besides mammals, also marine algae form lipid mediators such as prostaglandins and leukotrienes. In particular, microalgae are attractive candidates for the production of bioactive high-value metabolites. Here, we identified the diatom Cylindrotheca closterium as a prolific producer of SPMs. The diatom forms RvE3 and novel structurally related eicosanoids, including 14S/R,17R,18R-trihydroxy-eicosatetraenoic acid, which displays inflammation-resolving and anti-inflammatory bioactivities. This pro-resolving compound might enable advancements in anti-inflammatory therapy in mammals.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 34151208      PMCID: PMC8205247          DOI: 10.1021/acsptsci.1c00057

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  34 in total

Review 1.  Resolution of inflammation: the beginning programs the end.

Authors:  Charles N Serhan; John Savill
Journal:  Nat Immunol       Date:  2005-12       Impact factor: 25.606

2.  Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly.

Authors:  Roel P H De Maeyer; Rachel C van de Merwe; Rikah Louie; Olivia V Bracken; Oliver P Devine; Daniel R Goldstein; Mohib Uddin; Arne N Akbar; Derek W Gilroy
Journal:  Nat Immunol       Date:  2020-04-06       Impact factor: 25.606

Review 3.  Resolvins and protectins in inflammation resolution.

Authors:  Charles N Serhan; Nicos A Petasis
Journal:  Chem Rev       Date:  2011-07-18       Impact factor: 60.622

Review 4.  Prostaglandins and leukotrienes: advances in eicosanoid biology.

Authors:  C D Funk
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

Review 5.  Resolution phase lipid mediators of inflammation: agonists of resolution.

Authors:  Charles N Serhan; Nan Chiang
Journal:  Curr Opin Pharmacol       Date:  2013-06-06       Impact factor: 5.547

6.  Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain.

Authors:  Charles N Serhan; Jesmond Dalli; Sergey Karamnov; Alexander Choi; Chul-Kyu Park; Zhen-Zhong Xu; Ru-Rong Ji; Min Zhu; Nicos A Petasis
Journal:  FASEB J       Date:  2012-01-17       Impact factor: 5.191

7.  Phospholipases and galactolipases trigger oxylipin-mediated wound-activated defence in the red alga Gracilaria chilensis against epiphytes.

Authors:  Ulrich Lion; Theresa Wiesemeier; Florian Weinberger; Jessica Beltrán; Verónica Flores; Sylvain Faugeron; Juan Correa; Georg Pohnert
Journal:  Chembiochem       Date:  2006-03       Impact factor: 3.164

Review 8.  Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation.

Authors:  Takao Shimizu
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

9.  Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid.

Authors:  Yosuke Isobe; Makoto Arita; Shinnosuke Matsueda; Ryo Iwamoto; Takuji Fujihara; Hiroki Nakanishi; Ryo Taguchi; Koji Masuda; Kenji Sasaki; Daisuke Urabe; Masayuki Inoue; Hiroyuki Arai
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

10.  Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity.

Authors:  Oliver Werz; Jana Gerstmeier; Stephania Libreros; Xavier De la Rosa; Markus Werner; Paul C Norris; Nan Chiang; Charles N Serhan
Journal:  Nat Commun       Date:  2018-01-04       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.